# Diabetes Treatment and Management

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/diabetes-treatment-and-management/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the management of diabetes mellitus, with a particular emphasis on cardiovascular outcomes, glucose control, and the use of incretin hormones, SGLT2 inhibitors, and dipeptidyl peptidase-4 inhibitors. It also covers topics such as heart failure, glycemic control, insulin therapy, and clinical guidelines for the treatment of type 2 diabetes. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10401 |
| Works | 1,233 |

## Topic papers all

Showing 15 of 1233.

- [Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man](https://scholariq.org/papers/homeostasis-model-assessment-insulin-resistance-and-cell-function-from-fasting/)
- [Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-cardiovascular-outcomes-and-mortality-in-type-2-diabetes/)
- [Effects of Intensive Glucose Lowering in Type 2 Diabetes](https://scholariq.org/papers/effects-of-intensive-glucose-lowering-in-type-2-diabetes/)
- [Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-events-in-type-2-diabetes/)
- [10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes](https://scholariq.org/papers/10-year-follow-up-of-intensive-glucose-control-in-type-2-diabetes/)
- [Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy](https://scholariq.org/papers/effects-of-losartan-on-renal-and-cardiovascular-outcomes-in-patients-with-type-2/)
- [Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/liraglutide-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/intensive-blood-glucose-control-and-vascular-outcomes-in-patients-with-type-2/)
- [Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-patients-with-heart-failure-and-reduced-ejection-fraction/)
- [Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-versus-enalapril-in-heart-failure/)
- [Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/dapagliflozin-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy](https://scholariq.org/papers/canagliflozin-and-renal-outcomes-in-type-2-diabetes-and-nephropathy/)
- [Global aetiology and epidemiology of type 2 diabetes mellitus and its complications](https://scholariq.org/papers/global-aetiology-and-epidemiology-of-type-2-diabetes-mellitus-and-its/)
- [Dapagliflozin in Patients with Chronic Kidney Disease](https://scholariq.org/papers/dapagliflozin-in-patients-with-chronic-kidney-disease/)

## Topic primary papers

Showing 15 of 678.

- [Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-cardiovascular-outcomes-and-mortality-in-type-2-diabetes/)
- [Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-events-in-type-2-diabetes/)
- [10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes](https://scholariq.org/papers/10-year-follow-up-of-intensive-glucose-control-in-type-2-diabetes/)
- [Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/liraglutide-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/intensive-blood-glucose-control-and-vascular-outcomes-in-patients-with-type-2/)
- [Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-patients-with-heart-failure-and-reduced-ejection-fraction/)
- [Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/dapagliflozin-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy](https://scholariq.org/papers/canagliflozin-and-renal-outcomes-in-type-2-diabetes-and-nephropathy/)
- [Dapagliflozin in Patients with Chronic Kidney Disease](https://scholariq.org/papers/dapagliflozin-in-patients-with-chronic-kidney-disease/)
- [Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure](https://scholariq.org/papers/cardiovascular-and-renal-outcomes-with-empagliflozin-in-heart-failure/)
- [Once-Weekly Semaglutide in Adults with Overweight or Obesity](https://scholariq.org/papers/once-weekly-semaglutide-in-adults-with-overweight-or-obesity/)
- [Empagliflozin in Heart Failure with a Preserved Ejection Fraction](https://scholariq.org/papers/empagliflozin-in-heart-failure-with-a-preserved-ejection-fraction/)
- [Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes](https://scholariq.org/papers/multifactorial-intervention-and-cardiovascular-disease-in-patients-with-type-2/)
- [Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)](https://scholariq.org/papers/management-of-hyperglycaemia-in-type-2-diabetes-a-patient-centered-approach/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.